$NVS

An Update on RegenXBio

July 14, 2019 by Chris Stang Leave a Comment

Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? … [Read more...] about An Update on RegenXBio

Gene therapy treatment for SMA approved! (Full TA)

May 25, 2019 by Kevin Douglass Leave a Comment

Gene Therapy for SMA-- Full technical analysis #VolatilityWatch by follow_the_money on TradingView.com RegenexBio (RGNX) and Novartis (NVS) just received FDA approval of Gene Therapy treatment for … [Read more...] about Gene therapy treatment for SMA approved! (Full TA)

PDUFA Watch: Novartis’ Zolgensma (AVXS-101)

May 17, 2019 by Chris Stang Leave a Comment

Novartis' PDUFA date is May 2019While approval may not have a significant impact on Novartis' price, a patterns suggests there may be money to be made on Ionis' stock The time is drawing nearer to … [Read more...] about PDUFA Watch: Novartis’ Zolgensma (AVXS-101)

ASCO Alert: Stay Ahead of the Updates

May 9, 2019 by Chris Stang Leave a Comment

One of the most heralded oncology conferences is the annual American Society of Clinical Oncologists (ASCO). This year, Chicago is hosting the annual conference, which is running from May 31st through … [Read more...] about ASCO Alert: Stay Ahead of the Updates

Technically Swinging CNAT

February 21, 2019 by Kevin Douglass Leave a Comment

Swing Thesis This swing-trade for Conatus Pharmaceuticals, (Nasdaq: CNAT) is based on Technical Analysis (which aligns with some key dates) and a fundamental component. With regards to technical … [Read more...] about Technically Swinging CNAT

FDA Approves Cabozantinib; But it’s Not Alone

January 15, 2019 by Sultan Beardsley Leave a Comment

Leave a comment and click here to sub for MS article alerts and our newsletter! Overview January 14th, the FDA approved cabozantinib (CABOMETYX) for the treatment of hepatocellular carcinoma (HCC) in … [Read more...] about FDA Approves Cabozantinib; But it’s Not Alone

MS Morning Update-1/08/2019

January 8, 2019 by Sultan Beardsley Leave a Comment

NVS receives Breakthrough Therapy Designation (BTD) for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises in sickle cell disease Crizanlizumab is under development as a monthly … [Read more...] about MS Morning Update-1/08/2019

Post-ENCORE-PH Interview With CNAT

December 19, 2018 by Sultan Beardsley 1 Comment

Leave a comment and click here to sub for MS article alerts and our newsletter On the heels of the contentious revealing of ENCORE-PH top-line data MS Money Moves decided to go to the source for … [Read more...] about Post-ENCORE-PH Interview With CNAT

A Closer Look At CNAT’s “Failed” Clinical Study

December 14, 2018 by Sultan Beardsley 4 Comments

Introduction Conatus Pharmaceuticals (Nasdaq: CNAT) recently released highly anticipated top-line data from their Encore-PH clinical trial. The study investigated the efficacy and safety of … [Read more...] about A Closer Look At CNAT’s “Failed” Clinical Study

Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath

October 25, 2018 by Sultan Beardsley 1 Comment

Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath